You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Mallinckrodt
Medtronic
Harvard Business School

Last Updated: January 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for ATN-161

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for ATN-161?

ATN-161 is an investigational drug.

There have been 25 clinical trials for ATN-161. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Acute Kidney Injury, HIV Infections, and Liver Cirrhosis. The leading clinical trial sponsors are Attenuon, Westat, and Ablynx.

There are eighteen US patents protecting this investigational drug and two hundred and fifty-two international patents.

Recent Clinical Trials for ATN-161
TitleSponsorPhase
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)Emory UniversityPhase 1
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 1
Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)Johns Hopkins UniversityPhase 1

See all ATN-161 clinical trials

Clinical Trial Summary for ATN-161

Top disease conditions for ATN-161
Top clinical trial sponsors for ATN-161

See all ATN-161 clinical trials

US Patents for ATN-161

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ATN-161   Start Trial Fluorinated integrin antagonists SciFluor Life Sciences, Inc. (Cambridge, MA)   Start Trial
ATN-161   Start Trial Nonanoic and decanoic acid derivatives and uses thereof SciFluor Life Sciences, Inc. (Cambridge, MA)   Start Trial
ATN-161   Start Trial Method of making tetrahydronaphthyridinyl nonanoic acid compounds SciFluor Life Sciences, Inc. (Cambridge, MA)   Start Trial
ATN-161   Start Trial Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof SciFluor Life Sciences, Inc. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ATN-161

Drugname Country Document Number Estimated Expiration Related US Patent
ATN-161 Australia AU2014214737 2033-02-07   Start Trial
ATN-161 Brazil BR112015019039 2033-02-07   Start Trial
ATN-161 Canada CA2899321 2033-02-07   Start Trial
ATN-161 China CN105246889 2033-02-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
Mallinckrodt
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.